Search Results - "Blum, J.L."

Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: Results of an exploratory analysis by Glück, S, Russell, C, O'Shaughnessy, J, McKenna, E.F, Hu, S, Odom, D, Blum, J.L

“…Abstract We investigated treatment effects by oestrogen receptor (ER) status among women with metastatic breast cancer (MBC) receiving capecitabine (C) plus…”
Get full text

115. Long Term Patency of Decellularized Tissue Engineered Vascular Grafts in a Canine Model by Kypson, A.P, Blum, J.L, Li, Y, Strader, J.T, Lawson, J.H, Niklason, L.E, Dahl, S.L

Get full text

477 Capecitabine dose modification minimises side effects without compromising efficacy in pretreated metastatic breast cancer (MBC) by Leonard, R, Hennessy, B.T, Blum, J.L, O'Shaughnessy, J

Get full text

5024 Dose adjusting capecitabine minimises side effects while maintaining efficacy: retrospective review of capecitabine for pretreated metastatic breast cancer by O'Shaughnessy, J, Blum, J.L, Leonard, R, Hennessy, B.T

Get full text

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial by Litton, J.K., Hurvitz, S.A., Mina, L.A., Rugo, H.S., Lee, K.-H., Gonçalves, A., Diab, S., Woodward, N., Goodwin, A., Yerushalmi, R., Roché, H., Im, Y.-H., Eiermann, W., Quek, R.G.W., Usari, T., Lanzalone, S., Czibere, A., Blum, J.L., Martin, M., Ettl, J.

“…In EMBRACA, talazoparib prolonged progression-free survival versus chemotherapy (hazard ratio [HR] 0.542 [95% confidence interval (CI) 0.413-0.711]; P <…”
Get full text

461P Impact of comorbidities on real-world patient-reported outcomes of patients (pts) with hormone receptor-positive human epidermal growth factor 2-negative (HR+/HER2-) advanced breast cancer (ABC) enrolled in the POLARIS trial by Blum, J.L., Rocque, G., Ji, Y., Pluard, T., Migas, J., Lakhanpal, S., Jepsen, E., Gauthier, E., Wang, Y., Montelongo, M.Z., Cappelleri, J., Chen, C., Karuturi, M.S., Tripathy, D.

Get full text

373P Impact of comorbidities on real-world (rw) clinical outcomes of patients (pts) with hormone receptor-positive/human epidermal growth factor 2-negative (HR+/HER2-) advanced breast cancer (ABC) treated with palbociclib and enrolled in POLARIS by Tripathy, D., Blum, J.L., Karuturi, M.S., McCune, S., Kurian, S., Moezi, M.M., Anderson, D.M., Wang, Y., Montelongo, M.Z., Zhang, Z., Gauthier, E., Rocque, G.

Get full text

Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial by Ettl, J., Quek, R.G.W., Lee, K.-H., Rugo, H.S., Hurvitz, S., Gonçalves, A., Fehrenbacher, L., Yerushalmi, R., Mina, L.A., Martin, M., Roché, H., Im, Y.-H., Markova, D., Bhattacharyya, H., Hannah, A.L., Eiermann, W., Blum, J.L., Litton, J.K.

“…In the EMBRACA phase III trial, talazoparib (1mg daily, orally) demonstrated a statistically significant improvement in PFS versus physician’s choice of…”
Get full text

251P Real-world clinical outcomes of palbociclib plus endocrine therapy (ET) in hormone receptor–positive advanced breast cancer: Results from the POLARIS trial by Tripathy, D., Rocque, G., Blum, J.L., Karuturi, M.S., McCune, S., Kurian, S., Moezi, M.M., Anderson, D., Gauthier, E., Zhang, Z., Montelongo, M., Wang, Y.

Get full text

266P Real-world quality of life (QoL) in patients with HR+/HER2-advanced breast cancer (ABC) treated with palbociclib: Final clinical outcome assessment (COA) analysis from POLARIS by Rocque, G., Blum, J.L., Ji, Y., Pluard, T.J., Migas, J., Lakhanpal, S., Jepsen, E., Gauthier, E., Wang, Y., Montelongo, M., Cappelleri, J.C., Karuturi, M.S., Tripathy, D.

Get full text

190P Palbociclib treatment in pre/perimenopausal women with advanced/metastatic breast cancer (ABC/mBC): Real-world patient characteristics, treatment patterns, and outcomes data from POLARIS by Karuturi, M., Blum, J.L., Anderson, D., Kurian, S., Wilks, S.T., Wang, G., Gauthier, E., Zhang, Z., Wang, Y., Tripathy, D., Rocque, G.

Get full text

106P Palbociclib (PAL) in male patients (pts) with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC): Pt characteristics and treatment (Tx) patterns from the POLARIS study by Blum, J.L., Dicristo, C., Gordon, D., Karuturi, M., Oubre, D., Jepsen, E., Cuevas, J., Lakhanpal, S., Zhang, Z., Drucker, M., Wang, Y., Tripathy, D.

Get full text

365P - Measures of functional status in adults aged ≥70 years with advanced breast cancer (ABC) receiving palbociclib (PAL) combination therapy in POLARIS by Karuturi, M.S., Blum, J.L., Wallmark, J., McCune, S., Lakhanpal, S., Telivala, B., Tsai, M., Rakowski, T., Bardia, A., Cappelleri, J.C., Richardson, E., Wang, Y., Tripathy, D.

“…Few data are available on the treatment of ABC in older adults due to exclusion of this population from clinical trials. POLARIS is a real-world observational…”
Get full text

Measures of functional status in adults aged ≥70 years with advanced breast cancer (ABC) receiving palbociclib (PAL) combination therapy in POLARIS by Karuturi, M.S., Blum, J.L., Wallmark, J., McCune, S., Lakhanpal, S., Telivala, B., Tsai, M., Rakowski, T., Bardia, A., Cappelleri, J.C., Richardson, E., Wang, Y., Tripathy, D.

Get full text

Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study by Delaloge, S., Wolp-Diniz, R., Byrski, T., Blum, J.L., Gonçalves, A., Campone, M., Lardelli, P., Kahatt, C., Nieto, A., Cullell-Young, M., Lubinski, J.

“…Breast cancer is a heterogeneous disease defined by both germline and somatic abnormalities. In preclinical models, tumors carrying homologous recombination…”
Get full text

CONTESSA TRIO: A multinational, multicenter, phase II study of tesetaxel plus 3 different PD-(L)1 inhibitors in patients with metastatic triple negative breast cancer (TNBC) and tesetaxel monotherapy in elderly patients with her2- metastatic breast cancer (MBC) by Tolaney, S.M., Blum, J.L., Bondarenko, I., Chan, A., DaCosta, N., Feng, Y.-H., Izarzugaza, Y., Kim, S.-B., Liu, M.-C., Oliveira, M., Ow, S.G.W., Pavic, M., Peréz Lopéz, M.E., Rugo, H.S., Schwartzberg, L., Stradella, A., Kroll, S., O’Connell, J., Wei, T., Mittendorf, E.A.

Get full text

382TiP - CONTESSA TRIO: A multinational, multicenter, phase II study of tesetaxel plus 3 different PD-(L)1 inhibitors in patients with metastatic triple negative breast cancer (TNBC) and tesetaxel monotherapy in elderly patients with her2- metastatic breast cancer (MBC) by Tolaney, S.M., Blum, J.L., Bondarenko, I., Chan, A., DaCosta, N., Feng, Y.-H., Izarzugaza, Y., Kim, S.-B., Liu, M.-C., Oliveira, M., Ow, S.G.W., Pavic, M., Peréz Lopéz, M.E., Rugo, H.S., Schwartzberg, L., Stradella, A., Kroll, S., O’Connell, J., Wei, T., Mittendorf, E.A.

“…Chemotherapy (CT) treatments with robust efficacy that preserve quality of life are needed. Tesetaxel (T) is a novel, oral taxane that has potential advantages…”
Get full text

EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis by Gonçalves, A., Eiermann, W., Rugo, H.S., Ettl, J., Hurvitz, S.A., Yerushalmi, R., Martín, M., Al-Adhami, M., Tudor, I.C., Blum, J.L., Hannah, A.L., Litton, J.K.

Get full text

EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment by Martín, M., Eiermann, W., Rugo, H.S., Ettl, J., Hurvitz, S.A., Gonçalves, A., Yerushalmi, R., Markova, D., Tudor, I.C., Blum, J.L., Hannah, A.L., Litton, J.K.

Get full text

First report of real-world patient characteristics and treatment patterns from POLARIS: Palbociclib in hormone receptor-positive (HR+) advanced breast cancer: A prospective, multicenter, noninterventional study by Blum, J.L., McCune, S.L., Salkeni, M.A., Anderson, D.M., Migas, J.J., Lakhanpal, S., Patel, K., Bardia, A., Rocque, G., Wang, J., Cappelleri, J.C., Comstock, G., Wang, Y., Tripathy, D.

Get full text